Related Experiment Video
Updated: Jul 17, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Miltefosine in children with visceral leishmaniasis
Utpal Kant Singh1, Rajniti Prasad, Ranjeet Kumar
1Department of Pediatrics, Nalanda Medical College, Patna 800 020, India. patna@mapra.com
Insights
Miltefosine effectively treats visceral leishmaniasis in children, achieving high cure rates with manageable gastrointestinal side effects. Relapses and side effects like elevated ALT were observed but generally resolved.
Area of Science:
- Pediatric Infectious Diseases
- Parasitology
- Clinical Pharmacology
Background:
- Visceral leishmaniasis (kala-azar) is a serious parasitic disease affecting children.
- Effective and safe treatment options for pediatric visceral leishmaniasis are crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of Miltefosine in children with visceral leishmaniasis.
- To compare treatment outcomes in children with and without prior antileishmanial drug exposure.
Main Methods:
- A study involving 64 children diagnosed with visceral leishmaniasis.
- Patients were divided into two groups: treatment-naïve (Group I) and previously treated (Group II).
- All patients received oral Miltefosine, with follow-up for clinical response, splenic size, and parasite density.
Main Results:
- High parasitological cure rates were observed: 93.2% in Group I and 95% in Group II.
- Gastrointestinal side effects (diarrhea, vomiting) and pancytopenia were common.
- Transiently elevated ALT levels were noted in a significant proportion of patients, particularly in Group I.
Conclusions:
- Miltefosine is an effective treatment for pediatric visceral leishmaniasis, regardless of prior treatment history.
- Close monitoring for side effects like GI disturbances and elevated ALT is recommended.
- Further research into managing relapses and long-term outcomes is warranted.
Abstract:
Sixty four children (38 boys and 26 girls), aged 1 yr to 14 yr, presenting with fever, splenomegaly and positive LD body in splenic smear examination, admitted to pediatric ward of Nalanda Medical college and Child care center between 1st July 03 to 30th June 04 were taken for study. Patients were categorized into two groups: 44 were in Group I (Patients who had not received prior antileishmanial drug) and 20 in Group II (Patients who had received 30 days course of SAG; 20 mg per kg per day). All patients were given Miltefosine in dose of 2.5 per kg per day od or bid per orally to a maximum of 100 mg and were followed at completion of therapy, 1 month and 6 months for clinical response, splenic size and parasite density. 63 patients had parasitological cure with relapse in one patient of Group I during follow up. One patient in Group II had no response with first course but became parasitologically negative with 2nd course of Miltefosine. In Group I, one patient had persistent splenomegaly and found to have associated portal hypertension. GI side effects i.e. diarrhea and vomiting were observed in 26 and 23 patients respectively. Majority of patients had pancytopenia. Elevated ALT (> 3 times of normal) were seen in 28 and 11 patients of Group I and Group II respectively which returned to normal in subsequent follow up. The final cure rates were 93.2 percent and 95 percent in Groups I and II respectively.
More Related Videos
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
05:55In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase
Published on: April 4, 2025
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
Anthelminthic Agents
Rocky Mountain Spotted Fever
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism